Where previous research showed that PSMA therapy for prostate cancer can prolong the lives of patients who have exhausted all ...

The study published by Bastiaan M Privé and colleagues in The Lancet Oncology represents, to our knowledge, the first randomised phase 2 trial evaluating lutetium-177–PSMA-617 (177Lu-PSMA-617) in ...

A randomized study in 58 men with limited metastatic prostate cancer found that PSMA therapy postponed the need for hormone ...

India, April 2 -- Men with early-stage metastatic prostate cancer may soon be able to postpone the debilitating side effects ...

Clarity Pharmaceuticals (ASX: CU6) ('Clarity' or 'Company'), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for ...

The 2026 PSMA & Beyond conference featured a clinical development session and presentation by Dr. Jeremie Calais discussing a review of phase 1/2 compounds recently published. Without question, there ...

Tagawa, MD, identified 3 primary clinical scenarios where PSMA PET scans have become the established standard for prostate cancer care. The first application is initial s ...

The 2026 PSMA & Beyond conference featured a clinical development session and presentation by Dr. William Maguire discussing regulatory considerations related to PSMA PET imaging in clinical trials.

@2024 - All Right Reserved.

Reston, VA—Extended prostate-specific membrane antigen (PSMA)-targeted radiopharmaceutical therapy (177 Lu-PSMA) beyond six cycles is an effective and well-tolerated treatment for metastatic ...

A panel of experts offers guidance for selecting patients with mCRPC for treatment with 177Lu-PSMA-617 and for managing treatment-related toxicities. The treatment is approved for use in men with ...

Low- and high-volume disease in mHSPC, from CHAARTED to PSMA-PET: An international multicenter retrospective study. This is an ASCO Meeting Abstract from the 2024 ASCO Genitourinary Cancers Symposium.